Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93.8 PLN | -.--% | -.--% | -13.94% |
05-28 | Urteste S.A. Successfully Develops A Prototype Urine-Based Diagnostic Test for Detecting Brain Tumours | CI |
2021 | Urteste S.A. has completed an IPO in the amount of PLN 9.52 million. | CI |
Valuation
Fiscal Period: December | 2021 |
---|---|
Capitalization 1 | 109.4 |
Enterprise Value (EV) 1 | 100.8 |
P/E ratio | -47.1 x |
Yield | - |
Capitalization / Revenue | - |
EV / Revenue | - |
EV / EBITDA | -43.8 x |
EV / FCF | -43,718,878 x |
FCF Yield | -0% |
Price to Book | 11.3 x |
Nbr of stocks (in thousands) | 1,140 |
Reference price 2 | 95.90 |
Announcement Date | 18/03/22 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 |
---|---|---|
Net sales | - | - |
EBITDA 1 | -1.207 | -2.301 |
EBIT 1 | -1.222 | -2.321 |
Operating Margin | - | - |
Earnings before Tax (EBT) 1 | -1.221 | -2.322 |
Net income 1 | -1.221 | -2.322 |
Net margin | - | - |
EPS | - | -2.036 |
Free Cash Flow | - | -2.306 |
FCF margin | - | - |
FCF Conversion (EBITDA) | - | - |
FCF Conversion (Net income) | - | - |
Dividend per Share | - | - |
Announcement Date | 18/03/22 | 18/03/22 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 |
---|---|---|
Net Debt 1 | - | - |
Net Cash position 1 | 0.43 | 8.53 |
Leverage (Debt/EBITDA) | - | - |
Free Cash Flow | - | -2.31 |
ROE (net income / shareholders' equity) | - | -44.8% |
ROA (Net income/ Total Assets) | - | -27.3% |
Assets 1 | - | 8.507 |
Book Value Per Share | - | 8.500 |
Cash Flow per Share | - | 7.480 |
Capex 1 | 0.04 | 0.66 |
Capex / Sales | - | - |
Announcement Date | 18/03/22 | 18/03/22 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-13.94% | 33.55M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- URT Stock
- Financials Urteste S.A.